SEE Archives - Blue Horseshoe Stocks

Midweek Movers:

Wednesday shaped up to be another good day for us with regard to the potential options targets outlined in our premarket report. We had highlighted a slate of four possibilities, and they all produced some pretty good moves. Once again, our SPY Calls proved to be the best opportunities of the day.

We were looking at the SPY 11/12 $684-685 Calls, the OKLO Weekly $106-107 Calls, the ONON Weekly $39.50-40.50 Calls, and the ALC 11/21 $82.50 Calls. These were the best runs they recorded for Wednesday’s session:

SPY 11/12 $684-685 Calls
$684: .07-.44 (+529%)
$685: .01-.12 (+1100%)
_____

OKLO Weekly $106-107 Calls
$106: 5.00-10.49 (+110%)
$107: 5.15-11.20 (+117%)
_____

ONON Weekly $39.50-40.50 Calls
$39.50: 1.91-2.47 (+29%)
$40: 1.49-2.60 (+74%)
$40.50: 2.20-4.25 (+93%)
_____

ALC 11/21 $82.50 Calls
$82.50: 1.10-1.50 (+36%)

Fresh Options Ideas:
CSCO Weekly $678-679 Calls
DIS Weekly $111-110 Puts
FLUT Weekly $230 Puts
NICE 11/21 $125-130 Calls

Extended Watchlist:
MRSN, MWE, SOND, PTN, SGBX, MGRX, LVLU, FLY, SEE, TNMG, SOND, ONDS, SGBX

Aytu BioScience, Inc. AYTU Yesterday morning, we were just discussing AYTU and the modest progress the stock had made since we flagged it as a bottom play in Wednesday’s premarket report. Not only had it displayed a cherry bottom setup, but we noted a string of insider buysat the time as well.Following that report, we would witness a low of .4118, and over the course of the ensuing four trading days, the stock has made a noteworthy move and continues to exhibit signs that more gains could be in store.

Yesterday it reached .61, which represents a run of 48% in under a week. It did so on record volume, so we’re definitely eager to see where the momentum could carry this play that was already on its way back up.

InspireMD, Inc. NSPR

NSPR has been in real trouble in 2018, losing ground at seemingly every turn and unable to get out of its own way. However, through a combination of a South American breakthrough announcement for two of the companies drugs, and being just plain oversold, we’re seeing a marginal premarket gap-up and will want to observe for a more sustained rebound.

The news was pertaining to NSPR receiving regulatory approval from the goverment of Peru for its CGuard™ Embolic Prevention System (EPS) and MGuard Prime™ products. Peru has a population of more than 30 million people. (>>View PR)

Extended Watchlist:
ARWR, GLOW, MDGS, MBRX, SEE, WBAI, LIQT, PIXY,

Tag: SEE

Wednesday’s Winners, 4 New Earnings-Related Ideas

Blue Horseshoe Stocks: AYTU Update & More